^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
CLL-1, CD33 and/or CD123-specific CAR gene-engineered T cells
i
Other names: CLL-1, CD33 and/or CD123-specific CAR gene-engineered T cells
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
SZGIMI
Drug class:
CD123-targeted CAR-T immunotherapy, CD33-targeted CAR-T immunotherapy, CLL-1-targeted CAR-T immunotherapy
Related drugs:
